Metformin Causes Hepato-renal Dysfunctions in Obese Male Rats

• Autor(a) principal: El-Naggar,Sabry Ali
• Data de Publicação: 2021
• Outros Autores: Elwan,Mona, Basyouny,Mohamed Abo Elftouh, Elshennawy,Ehab Othman, El-Said,Karim Samy
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Archives of Biology and Technology
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132021000100320
• topic: Metformin; Hepato-renal; Obesity; Antioxidants; Dysfunction

Abstract Obesity results in detrimental effects on different body organs. Metformin (Met) has described to decrease the body weight of obese patient and to control the glucose level. This study aimed to evaluate the role of Met treatment for long period on the functionality of liver and kidney organs of obese rats. Forty rats were used in this study and divided into four groups as the following: group 1 (Gp1) was served as a negative control that administered orally with 200 µL of H2O. Gp2 of rats was administered with Met (200 mg/kg) daily for a month. Gp3 was obese rats, and Gp4 was obese rats administered with Met as in Gp2. All rats were sacrificed to analyze hematological, biochemical, and histopathological changes. The results showed that Met decreased the body weight of both naïve and obese rats, however, it caused hepato-renal dysfunctions in obese rats as evidenced by increased the levels of ALT, AST, urea, creatinine, and MDA and decrease in the antioxidants biomarkers (SOD, Cat and GSH). Collectively, Met causes liver and kidneys dysfunctions of obese rats and is not recommended to described for obese persons.